MRC Human Genetics Unit
Medical Research Council Human Genetics Unit

Genome editing and targeted protein degradation

Our research has three themes:

Theme 1: Degron Tagging

​​​Most strategies to perturb gene function target nucleic acids, whereas proteins are the effectors of most biological functions. Degron tagging enables the dose of specific proteins to be controlled using small molecule ligands that induce turnover via the ubiquitin / proteasome system. Degradation of tagged proteins is often rapid (e.g. t½ < 30 minutes), can be tuned to intermediate/hypomorphic levels, and is reversible once the ligand is removed. This provides greater versatility than many other gene perturbation strategies, making it easier to identify the direct and immediate consequences of protein removal, and allowing protein function to be removed and reinstated to better model gene therapy and drug activity.

Precision control of protein dosage using degron tagging
Precision control of protein dosage using degron tagging. A. Genome editing is used to fuse a cassette encoding a degron tag to a gene of interest. B. Addition of ligand (indole-3-acetic acid: IAA) induces rapid and profound reduction in the dose of two AID-tagged proteins in CD8+ thymocytes following intraperitoneal delivery of IAA. C. Protein degradation activity can be titrated using different IAA dosage. D. Protein degradation is fully reversible following IAA treatment in vivo

Theme 2: Genome Editing

Cas9 chromatin
Heterochromatin impedes CRISPR mutagenesis when Cas9 exposure is low.

Genome editing enables the sequence of chromosomal DNA to be modified in living cells using engineered nucleases. During his postdoctoral work (UC Berkeley, 2008 – 2011) Andrew led efforts to develop the first protocols for germline genome editing in nematode worms, showing that they could be transferred between species to study the evolution of developmental pathways (Wood, Lo, Zeitler et al, Science, 2011). This work with Zinc Finger and TALE nucleases helped to pave the way for the CRISPR revolution, especially in ‘non-traditional’ model organisms. Since then, the laboratory has helped to pioneer epigenome editing tools in mammalian stem cell models (Therizols et al, Science 2014), and elucidated the contribution of chromatin state to the frequency and type of mutations that arise during CRISPR-Cas9 genome editing (Kallimasioti-Pazi et al, PLoS Biology 2018). Current projects use genome editing technology for deep mutational scanning to better understand genotype/phenotype relationships in human disease genes.

Theme 3: Mitotic Chromosome Condensation

Successful completion of the cell cycle is essential for multicellular development. However, heritable mutations affecting genes encoding essential cell cycle proteins can cause tissue-specific diseases such as microcephaly, immunodeficiency and cancer predisposition, but the basis for these tissue-specific phenotypes is poorly understood. We discovered (with Bickmore and Jackson) that germline mutations affecting subunits of the condensin complexes, which restructure the genome in preparation for cell division, cause developmental disease through abnormal mitosis (Woodward et al Genes & Development 2016, Martin et al Genes & Development 2016). In mice, thymic T cell divisions are particularly affected by condensin mutation, whereas in human, neurogenesis is disproportionately compromised. We also showed for the first time that perturbation of mitotic chromosome structure was sufficient to drive tumourigenesis in mice (Woodward Genes Dev. 2016 Oct 1;30(19):2173). Somatic mutations in condensin subunits occur at elevated rates in human cancer (Leiserson, Nat Genet. 2015 Feb;47(2):106), so our data support that these rare mutations are bona fide drivers of tumourigenesis.

Condensin
Condensins are pentameric DNA motor protein complexes that restructure the interphase genome into rod shaped chromosomes during mitosis. Condensin mutations cause human disease via mitotic abnormalities such as anaphase bridges.